GMI presents results of lead compound in animal models of inflammatory diseases at ASH 2007.
All current GMI investors return to participate in its Series B.
Our roster of executives and directors include internationally-recognized names in pharmaceuticals, biotechnology and glycobiology.		  
More GMI News >>
    
Meet Our Management >>
  
         
 

Therapeutics Through Glycobiology

Scientists have known for decades of the importance of carbohydrates in organisms as a source of both food and structural material. More recently, the scientific community has begun to recognize the role carbohydrates play in advanced cellular function - from cell differentiation to disease regulation.

GMI believes it's possible to build small molecule drugs that mimic these advanced functions of carbohydrates. Our initial focus is to develop glycomimetic therapeutics to treat a broad range of inflammatory and infectious diseases. We now have in hand a number of proprietary small molecules that we believe have significant therapeutic potential.

More about GMI and Glycobiology >>

  
 

 
   
 
We're assembling an on-line repository of publications and abstracts relating to our efforts as they become available.
How to reach us by phone, fax or e-mail, plus maps and directions to our offices. Please note that unsolicited bulk e-mail and bulk faxes are not welcome.		  
 
Browse The Stacks >>
  
Contact Information >>